Checkpoint inhibitor toxicity
[DOC File]Theranostics
https://info.5y1.org/checkpoint-inhibitor-toxicity_1_51f2d3.html
Checkpoint inhibitors such as Nivolumab, a human IgG4 monoclonal antibody directed against PD-1 either as a monotherapy or in combination with ipilimumab, a CTLA-4 inhibitor and in combination with other immune targets have been shown to be effective to controlling cancer.
[DOCX File]Abstract - Imperial College London
https://info.5y1.org/checkpoint-inhibitor-toxicity_1_26063f.html
51. Puzanov I, Diab A, Abdallah K, Bingham C, Brogdon C, Dadu R, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5: 95. 52.
ALX Oncology
18.Gowen MF, Giles KM, Simpson D, Tchack J, Zhou H, Moran U, et al. Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. J Trans Med. 2018; 16(1): 82. 19.Tray N, Weber JS, Adams S. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application.
az659834.vo.msecnd.net
“We believe ALX148, our lead development candidate, is emerging as a next-generation checkpoint inhibitor designed to have high affinity for CD47 and to overcome hematologic toxicity limitations associated with other CD47 blocking approaches in the clinic. With the successful completion of our initial public offering in July, we have a strong ...
ir.sutrobio.com
Scientists at other companies have focused research on finding ways to modify cytokines so as to reduce toxicity while maintaining therapeutic benefit. The observed efficacy of a modified cytokine in combination with an immune checkpoint inhibitor indicates the potential of this new approach.
Investor Relations | Sutro Biopharma
Patients must have histologically proven stage II (T3N0 only), IIIA, or IIIB invasive anal (anal margin) squamous cell carcinoma. This may include tumors of non-keratinizing histology such as basoloid, transitional cell, or cloacogenic histology.
[DOCX File]Agrawal L, …
https://info.5y1.org/checkpoint-inhibitor-toxicity_1_947720.html
Immune checkpoint inhibitors and cardiovascular toxicity. Alexander R. Lyon PhD 1,2*, Nadia Yousaf MD 3, Nicolò M.L. Battisti MRCP 3, Javid Moslehi PhD 4 and James Larkin PhD 3. Cardio-Oncology Service, Royal Brompton Hospital, London, UK. National …
[DOC File]Theranostics
https://info.5y1.org/checkpoint-inhibitor-toxicity_1_138559.html
Scientists at other companies have focused research on finding ways to modify cytokines so as to reduce toxicity while maintaining therapeutic benefit. The observed efficacy of a modified cytokine in combination with an immune checkpoint inhibitor indicates the potential of this new approach.
[DOCX File]CRCWM
https://info.5y1.org/checkpoint-inhibitor-toxicity_1_338380.html
The study is being conducted in patients with urothelial, gastric or gastroesophageal or non-small cell lung cancer that have previously failed treatment with a checkpoint inhibitor. Dose escalation of paclitaxel administered as a flat dose of 270 mg per day for …
Toxicity management of immunotherapy for patients with metastat…
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Nearby & related entries:
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.